Pien Tze Huang’s PZH2108 Cancer Pain Drug Enrolls First Phase IIa Patient
Zhangzhou Pien Tze Huang Pharmaceutical Co., Ltd. (SHA: 600436) announced the enrollment of the first...
Drug
Henlius Serplulimab Wins BTD for Gastric Cancer Perioperative Treatment, a China First
Shanghai Henlius Biotech, Inc. (HKG: 2696) announced that its anti‑PD‑1 monoclonal antibody serplulimab (HANSIZHUANG, Hetronifly...
Pfizer’s Hympavzi Wins China Approval as First Weekly Non‑Factor Hemophilia Therapy
Pfizer Inc. (NYSE: PFE) announced that Hympavzi (marstacimab), the world’s first non‑factor hemophilia therapy requiring...
Kelun-Biotech’s Trastuzumab Botidotin HER2 ADC Launches in China After Phase 3 Win vs T-DM1
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (HKG: 6990) announced the official China launch of trastuzumab botidotin,...
Regeneron’s Libtayo Wins EC Approval for Adjuvant CSCC, 68% Risk Reduction
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced the European Commission (EC) approved Libtayo (cemiplimab) as adjuvant...
Lynk’s LNK01004 Pan-JAK Inhibitor Shows EASI-75 Win in Phase 2 Atopic Dermatitis Trial
Lynk Pharmaceuticals Co., Ltd. announced positive Phase II data for its self‑developed Class 1 innovative drug LNK01004,...
Sino Biopharm’s LM-350 CDH17-ADC Wins NMPA Nod for Clinical Trials
Sino Biopharmaceutical Limited (HKG: 1177) announced that its self‑developed LM‑350, a CDH17‑targeting Antibody‑Drug Conjugate (ADC),...
Cutia’s CU-40105 Topical Finasteride Spray NDA Accepted by NMPA, a China First
Cutia Therapeutics (HKG: 2487) announced that the National Medical Products Administration (NMPA) has accepted its...
Roche’s Lunsumio SC Wins EU Conditional Approval for Follicular Lymphoma
Roche Holding AG (SWX: ROG, OTCMKTS: RHHBY) announced that the European Commission (EC) has granted...
Roche’s giredestrant SERD Achieves iDFS Win in Phase 3 lidERA Breast Cancer Trial
Roche (SWX: ROG, OTCMKTS: RHHBY) announced its investigational oral SERD giredestrant met the primary endpoint...
Hengrui’s HRS-6209 CDK4 Inhibitor Wins NMPA Nod for Breast Cancer Combo Trial
Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) announced that HRS‑6209 capsules, a novel...
Hengrui’s HRS-4642 KRAS G12D Inhibitor Wins NMPA Nod for Phase 1b/2 Solid Tumor Trials
Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) announced that HRS‑4642, a home‑developed KRAS...
BeOne’s Zanidatamab Achieves PFS & OS Wins in HERIZON-GEA-01 Phase 3 HER2-Positive Cancer Trial
BeOne Medicines Ltd. (NASDAQ: ONC, HKG: 6160, SHA: 688235) announced its HER2‑targeted bispecific antibody zanidatamab (Ziihera)...
Biokin’s iza-bren ADC Achieves Dual PFS & OS Endpoints in Phase 3 Esophageal Cancer, a Global First
Sichuan Biokin Pharmaceutical Co., Ltd. (SHA: 688506) announced its antibody-drug conjugate iza-bren (izalontamab brengitecan, BL‑B01D1)...
BMS and J&J Halt Phase III Milvexian Anticoagulant Trial for Acute Coronary Syndrome Patients
Bristol‑Myers Squibb (BMS, NYSE: BMY) and Johnson & Johnson (J&J, NYSE: JNJ) announced the premature...
Jiangsu Hengrui Secures NMPA Approval for Tegileridine in Mechanically Ventilated ICU Patients
Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) announced that its μ‑opioid receptor (MOR)‑biased...
Lundbeck’s Vyepti Secures Chinese NDA, Expands Asian Footprint
Lundbeck A/S (OTCMKTS: HLUBF) announced that the Center for Drug Evaluation (CDE) of China’s National...
Akeso Secures NMPA Approval for AK152 – First Bispecific Antibody Targeting Alzheimer’s in China
Akeso Inc. (HKG: 9926) announced that its self‑developed bispecific antibody AK152 has received regulatory approval...
Abbisko Therapeutics Reports Durable Response in Phase 3 MANEUVER Study for Pimicotinib (ABSK021) in TGCT
Abbisko Therapeutics Co., Ltd. (HKG: 2256) released long‑term efficacy, safety and patient‑reported outcome data from its...
Zhejiang Jianfeng Group Secures NMPA Approval for JFAN‑1001/ Vinorelbine Combination in Advanced NSCLC
Zhejiang Jianfeng Group Co., Ltd. (SHA: 600668) announced that its subsidiary Jianfeng Yien Biotechnology has obtained...